$AVBP

$21.00▲ +9.3% YTD

8 SEC 13D/G filings tracked · Last updated Oct 25, 2026

Filing History

CP $21.00▲ +9.3%Oct 25, 2026 · ThinkSabio Blog

$AVBP - ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026…

News

AVBP ▲ +2.8% - ArriVent BioPharma, Inc.

CP $18.43▲ +2.8%Oct 20, 2026 · ThinkSabio Blog

$AVBP highs…

News

AVBP ▲ +0.7% - ArriVent BioPharma, Inc.

CP $16.80▲ +0.7%Oct 19, 2026 · ThinkSabio Blog

$AVBP - ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer…

SEC 13D/G

AVBP - ArriVent BioPharma, Inc. - SEC Filing Update (13-OCT-2026) | ThinkSabio - Stocks Simplified

$16.09▼ -22.57%Oct 13, 2026 · ThinkSabio Blog

$AVBP SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #AVBP ArriVent BioPharma, Inc. : $16.09 Sector: Healthcare | YTD…

News

AVBP ▼ -1.5% - ArriVent BioPharma, Inc.

CP $16.46▲ -1.5%Oct 12, 2026 · ThinkSabio Blog

$AVBP - ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002…

SEC 13D/G

AVBP - ArriVent BioPharma, Inc. - SEC Filing Update (08-OCT-2026) | ThinkSabio - Stocks Simplified

$16.90▼ -18.67%Oct 8, 2026 · ThinkSabio Blog

$AVBP SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #AVBP ArriVent BioPharma, Inc. : $16.90 Sector: Healthcare | YTD…

News

AVBP ▲ +0.8% - ArriVent BioPharma, Inc.

CP $28.70▲ +0.8%Oct 6, 2026 · ThinkSabio Blog

$AVBP - ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC…

SEC 13D/G

$AVBP SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks Simplified

$30.16▲ 45.14%Jul 27, 2026 · ThinkSabio Blog

$AVBP SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #AVBP : $30.16 Sector: Healthcare | YTD: 🔼+ 45.14% The SEC discl…